Gun-Wook Kang

Director/Board Member at KOREA UNITED PHARM INC.

54 year

Health Technology

Consumer Services

Profile

Gun-Wook Kang is associated with three organizations, namely KOREA UNITED PHARM, Inc., Pelemed Co., Ltd., and Seoul National University.
He holds the position of Independent Director in KOREA UNITED PHARM, Inc. and Pelemed Co., Ltd.
and is a Professor at Seoul National University.

Gun-Wook Kang active positions

Companies	Position	Start
KOREA UNITED PHARM INC.	Director/Board Member	-
Seoul National University	Corporate Officer/Principal	-
Pelemed Co., Ltd. Pelemed Co., Ltd. Pharmaceuticals: GenericHealth Technology Pelemed Co., Ltd. is a South Korean company based in Seoul that specializes in the development of innovative anticancer drugs. Pelemed's technology platform, PeLeSeLect & AHEDD, overcomes mutation-mediated drug resistance and enables precision drug design for kinase-targeted therapies. The company's pipeline includes several drugs in various stages of development for the treatment of different types of cancer. Pelemed has received funding from the IP Voucher Funded by MSS and has a scientific advisory board that includes experts from the ASAN Medical Center Bio Core Facility. The company was founded in 2019, and its CEOs are Yong-Chul Kim and Soo-Yeon Jang.	Director/Board Member	-

All active positions of Gun-Wook Kang

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Gun-Wook Kang's experience

Connections

100 +

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Listed companies	1
KOREA UNITED PHARM INC.	Health Technology

Private companies	1
Pelemed Co., Ltd. Pelemed Co., Ltd. Pharmaceuticals: GenericHealth Technology Pelemed Co., Ltd. is a South Korean company based in Seoul that specializes in the development of innovative anticancer drugs. Pelemed's technology platform, PeLeSeLect & AHEDD, overcomes mutation-mediated drug resistance and enables precision drug design for kinase-targeted therapies. The company's pipeline includes several drugs in various stages of development for the treatment of different types of cancer. Pelemed has received funding from the IP Voucher Funded by MSS and has a scientific advisory board that includes experts from the ASAN Medical Center Bio Core Facility. The company was founded in 2019, and its CEOs are Yong-Chul Kim and Soo-Yeon Jang.	Health Technology